Pharmaceuticals & Biotechnology • Mid Cap
Biocon Ltd.
Performance
Stories & Reports






Announcements
Biocon Limited has informed the Exchange regarding a press release dated November 16, 2026, titled "Biocon Gets U.S. FDA Approval for Pebrilzo (pertuzumab-qcay) Injection, a Biosimilar to Perjeta®, Expanding Its Oncology Portfolio".
View Full DocBiocon Ltd. Share Price
As of 18 November 2026, Biocon Ltd. share price is ₹359.40. The stock opened at ₹362.20, compared to its previous close of ₹362.20. During today's trading session, Biocon Ltd. share price moved in the range of ₹358.40 to ₹363.15.
Looking at its last 52-week performance, the stock has touched a low of ₹318.40 and a high of ₹447.15. On the performance front, Biocon Ltd. share price is down 14.62% on a year-on-year basis.
The market capitalization of Biocon Ltd. is ₹49908.85 Cr, with a P/E ratio of 37.18.
Moving Averages




